» Articles » PMID: 39040452

Recent Progress in Surface-Enhanced Raman Spectroscopy Detection of Biomarkers in Liquid Biopsy for Breast Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2024 Jul 23
PMID 39040452
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the most commonly diagnosed cancer in women globally and a leading cause of cancer-related mortality. However, current detection methods, such as X-rays, ultrasound, CT scans, MRI, and mammography, have their limitations. Recently, with the advancements in precision medicine and technologies like artificial intelligence, liquid biopsy, specifically utilizing Surface-Enhanced Raman Spectroscopy (SERS), has emerged as a promising approach to detect breast cancer. Liquid biopsy, as a minimally invasive technique, can provide a temporal reflection of breast cancer occurrence and progression, along with a spatial representation of overall tumor information. SERS has been extensively employed for biomarker detection, owing to its numerous advantages such as high sensitivity, minimal sample requirements, strong multi-detection ability, and controllable background interference. This paper presents a comprehensive review of the latest research on the application of SERS in the detection of breast cancer biomarkers, including exosomes, circulating tumor cells (CTCs), miRNA, proteins and others. The aim of this review is to provide valuable insights into the potential of SERS technology for early breast cancer diagnosis.

Citing Articles

Advancing Breast Cancer Diagnosis: Optimization of Raman Spectroscopy for Urine-Based Early Detection.

Andras D, Cozan R, Muresan D, Moisoiu V, Crisan G, Bintintan V Biomedicines. 2025; 13(2).

PMID: 40002920 PMC: 11852463. DOI: 10.3390/biomedicines13020505.

References
1.
Hernandez-Arteaga A, Zermeno-Nava J, Martinez-Martinez M, Hernandez-Cedillo A, Ojeda-Galvan H, Jose-Yacaman M . Determination of Salivary Sialic Acid Through Nanotechnology: A Useful Biomarker for the Screening of Breast Cancer. Arch Med Res. 2019; 50(3):105-110. DOI: 10.1016/j.arcmed.2019.05.013. View

2.
Su X, Liu X, Xie Y, Chen M, Zheng C, Zhong H . Integrated SERS-Vertical Flow Biosensor Enabling Multiplexed Quantitative Profiling of Serological Exosomal Proteins in Patients for Accurate Breast Cancer Subtyping. ACS Nano. 2023; 17(4):4077-4088. DOI: 10.1021/acsnano.3c00449. View

3.
Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

4.
Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

5.
Lan G, Ni K, Xu R, Lu K, Lin Z, Chan C . Nanoscale Metal-Organic Layers for Deeply Penetrating X-ray-Induced Photodynamic Therapy. Angew Chem Int Ed Engl. 2017; 56(40):12102-12106. PMC: 5666692. DOI: 10.1002/anie.201704828. View